Stockreport

Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients [Seeking Alpha]

Gain Therapeutics, Inc.  (GANX) 
PDF GT-02287's mechanism addresses GCase misfolding earlier in the disease process, potentially offering superior efficacy versus competitors. GANX's $66 million market c [Read more]